*Result*: Type II mode of JAK2 inhibition and destabilization are potential therapeutic approaches against the ruxolitinib resistance driven myeloproliferative neoplasms
*Author/editor-in-chief*:
*Publication*:
Freiburg : Universität, 2024
*Physical description scale*:
1 Online-Ressource
*Format*:
*Language*:
*eng*
*Notes*:
Frontiers in oncology. - 14 (2024) , 1430833, ISSN: 2234-943X
*DOI*:
10.3389/fonc.2024.1430833